Of note, inhibition of the PI3K/AKT/mTOR and RAS/MEK/ERK pathways was observed in paired tumor biopsies.[42] Pan PI3K inhibitors, such as pilaralisib (SAR245408), were tested in combination with trastuzumab and chemotherapy, with results showing objective evaluable responses.[43]. The gene discussed is PIK3CA; the disease is neoplasm.